|
|
| Type |
Symposium |
| Area |
Current Trends in Drug Repositioning |
| Room No. |
Room 306B |
| Time |
THU 16:05-: |
| Code |
MEDI-2 |
| Subject |
AI-driven Drug Repositioning and Beyond |
| Authors |
Sang Ok Song
Standigm, Inc., Korea |
| Abstract |
With all the hype around AI, the adoption of AI within pharmaceutical industries has been increasing. How the AI-driven technologies are now explored at the entire stages of drug discovery and development is briefly reviewed focusing on major research partnerships between leading AI startups and big pharmaceutical companies.
Standigm is one of leading companies in the “AI for drug discovery” space. The AI-based drug repositioning platform which is composed of three core AI modules, (1) Indication Prediction, (2) Prediction Interpretation, (3) Target Prioritization, generated tens of repurposed drug candidates for cancers, Parkinson’s disease, Non-alcoholic Fatty Liver disease and more, which have been experimentally validated. The most recent progress will be shared.
Beyond repurposing of existing drugs, designing novel drugs is near at hand. How new molecules with better desired properties can be optimized from prototype molecules such as hits or leads will be summarized with example studies.
In conclusion, technological and organizational challenges to overcome for successful AI application to drug discovery and development will be discussed. Standigm sees big progress towards overcoming them in coming years. |
| E-mail |
sangok.song@standigm.com |
|
122nd General Meeting of the KCS